Citation

Stephens DB, De Leon J. Pharmacogenomics 2016; 17(12): 1295-1304.

Affiliation

Department of Psychiatry, University of Kentucky College of Medicine, Lexington, KY, USA.

Copyright

(Copyright © 2016, Future Medicine)

DOI

10.2217/pgs-2016-0086

PMID

27463022

Abstract

AIM: Suicide accounts for over 800,000 deaths per year worldwide and is the tenth-leading cause of mortality in USA. Several studies have investigated cytochrome P450 CYP2D6 ultra-rapid metabolizer (UM) phenotype in relation to suicidality, with mixed results. This study tested the hypothesis of increased suicide risk among CYP2D6 UMs. PATIENTS & METHODS: Among the 4264 state psychiatric hospital inpatients included, 2435 (57%) reported a prior suicide attempt.

RESULTS: No association between UM status and attempted suicide was observed in bivariate (odds ratio: 0.87; 95% CI: 0.53-1.25), multivariate (adjusted odds ratio: 0.89; 95% CI: 0.55-1.46), or risk-stratified analyses.

CONCLUSION: These results contrast with prior reports of increased suicidality among CYP2D6 UMs and highlight the pressing need to identify reliable screening methods to better address this persistent public health problem.

Language: en